Trials / Completed
CompletedNCT02418845
A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 189 (actual)
- Sponsor
- Symbiomix Therapeutics · Industry
- Sex
- Female
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to test the safety and efficacy of the oral investigational new drug, SYM-1219 for the treatment of bacterial vaginosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYM-1219 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-05-28
- Primary completion
- 2015-10-05
- Completion
- 2015-12-05
- First posted
- 2015-04-16
- Last updated
- 2021-10-15
- Results posted
- 2021-04-13
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02418845. Inclusion in this directory is not an endorsement.